Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Breast Cancer

Free Subscription 31.05.2021 1 Am J Pathol 9 Ann Surg Oncol 3 BMC Cancer 4 Br J Cancer 1 Breast Cancer 1 Breast Cancer (Dove Med Press) 3 Breast Cancer Res 4 Breast Cancer Res Treat 3 Cancer 1 Cancer Chemother Pharmacol 2 Cancer Lett 6 Clin Breast Cancer 1 CMAJ 1 Eur J Surg Oncol 2 Gene 1 Int J Cancer 1 Int J Radiat Oncol Biol Phys 1 J Clin Oncol 1 J Natl Cancer Inst 2 J Surg Oncol 3 NPJ Breast Cancer 1 Oncol Rep 3 PLoS One 2 Radiology 1 Science

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Pathol

1. JANA S, Muscarella RA Jr, Jones D
   The multifaceted effects of breast cancer on tumor draining lymph nodes.
   Am J Pathol. 2021 May 24. pii: S0002-9440(21)00209.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

2. SATTAVAN S, Agarwal G
   Comments on "Breast-Conserving Therapy is Associated with Improved Survival compared with Mastectomy for Early-Stage Breast Cancer: A Propensity Score Matched Comparison Using the National Cancer Database".
   Ann Surg Oncol. 2021 May 24. pii: 10.1245/s10434-021-10149.
   PubMed        
   
   
3. LEON P, Panaro F
   ASO Author Reflections: Exploring the Oncologic Impact of Pancreatic Fistula after Distal Pancreatectomy for Ductal Adenocarcinoma.
   Ann Surg Oncol. 2021;28:3184-3185.
   PubMed        
   
   
4. MILLER ME, Dietz J
   ASO Author Reflections: Magnetic Seed Localization and Tracers Add Value to Multidisciplinary Breast Programs.
   Ann Surg Oncol. 2021;28:3230-3231.
   PubMed        
   
   
5. PALSHOF FK, Lanng C, Kroman N, Benian C, et al
   ASO Visual Abstract: Prediction of Pathologic Complete Response in Breast Cancer Patients Comparing Magnetic Resonance Imaging with Ultrasound in the Neoadjuvant Setting.
   Ann Surg Oncol. 2021 May 21. pii: 10.1245/s10434-021-10158.
   PubMed        
   
   
6. PALSHOF FK, Kroman N, Tvedskov TF
   ASO Author Reflections: The Role of Imaging Modalities in Omitting Surgery in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
   Ann Surg Oncol. 2021 May 22. pii: 10.1245/s10434-021-10178.
   PubMed        
   
   
7. SHOWALTER SL, Meneveau MO, Keim-Malpass J, Camacho TF, et al
   Correction to: Effects of Adjuvant Endocrine Therapy Adherence and Radiation on Recurrence and Survival Among Older Women with Early-Stage Breast Cancer.
   Ann Surg Oncol. 2021 May 22. pii: 10.1245/s10434-021-10216.
   PubMed        
   
   
8. BUCCI LK, Brunelle CL, Bernstein MC, Shui AM, et al
   ASO Visual Abstract: Subclinical Lymphedema After Treatment for Breast Cancer: Risk of Progression and Considerations for Early Intervention.
   Ann Surg Oncol. 2021 May 23. pii: 10.1245/s10434-021-10196.
   PubMed        
   
   
9. BUCCI LK, Taghian AG
   ASO Author Reflections: The Promising Potential of Early Intervention for Subclinical Lymphedema in Women Who Underwent Nodal Surgery for Breast Cancer.
   Ann Surg Oncol. 2021 May 25. pii: 10.1245/s10434-021-10176.
   PubMed        
   
   
10. PALSHOF FK, Lanng C, Kroman N, Benian C, et al
    Prediction of Pathologic Complete Response in Breast Cancer Patients Comparing Magnetic Resonance Imaging with Ultrasound in Neoadjuvant Setting.
    Ann Surg Oncol. 2021 May 27. pii: 10.1245/s10434-021-10117.
    PubMed         Abstract available
    
    

    
    BMC Cancer

11. CHOI SH, Yoon HS, Yoo SA, Yun SH, et al
    Co-relation with novel phosphorylation sites of IkappaBalpha and necroptosis in breast cancer cells.
    BMC Cancer. 2021;21:596.
    PubMed         Abstract available
    
    
12. HAN P, Zhu J, Feng G, Wang Z, et al
    Characterization of alternative splicing events and prognostic signatures in breast cancer.
    BMC Cancer. 2021;21:587.
    PubMed         Abstract available
    
    
13. ANWAR SL, Cahyono R, Prabowo D, Avanti WS, et al
    Metabolic comorbidities and the association with risks of recurrent metastatic disease in breast cancer survivors.
    BMC Cancer. 2021;21:590.
    PubMed         Abstract available
    
    

    
    Br J Cancer

14. VAIDYA JS, Bulsara M, Baum M, Wenz F, et al
    New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer.
    Br J Cancer. 2021 May 25. pii: 10.1038/s41416-021-01440.
    PubMed         Abstract available
    
    
15. GATHANI T, Reeves G, Broggio J, Barnes I, et al
    Ethnicity and the tumour characteristics of invasive breast cancer in over 116,500 women in England.
    Br J Cancer. 2021 May 26. pii: 10.1038/s41416-021-01409.
    PubMed         Abstract available
    
    
16. GIANNAKEAS V, Lim DW, Narod SA
    The risk of contralateral breast cancer: a SEER-based analysis.
    Br J Cancer. 2021 May 26. pii: 10.1038/s41416-021-01417.
    PubMed         Abstract available
    
    
17. DAVIDSON BA, Croessmann S, Park BH
    The breast is yet to come: current and future utility of circulating tumour DNA in breast cancer.
    Br J Cancer. 2021 May 26. pii: 10.1038/s41416-021-01422.
    PubMed         Abstract available
    
    

    
    Breast Cancer

18. AMIOKA A, Kadoya T, Sueoka S, Kobayashi Y, et al
    Effect of Wnt5a on drug resistance in estrogen receptor-positive breast cancer.
    Breast Cancer. 2021 May 28. pii: 10.1007/s12282-021-01241.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

19. CHEN MY, Gillanders WE
    Staging of the Axilla in Breast Cancer and the Evolving Role of Axillary Ultrasound.
    Breast Cancer (Dove Med Press). 2021;13:311-323.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

20. PANJARIAN S, Madzo J, Keith K, Slater CM, et al
    Accelerated aging in normal breast tissue of women with breast cancer.
    Breast Cancer Res. 2021;23:58.
    PubMed         Abstract available
    
    
21. JACQUEMETTON J, Kassem L, Poulard C, Dahmani A, et al
    Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant.
    Breast Cancer Res. 2021;23:57.
    PubMed         Abstract available
    
    
22. AL-ZAHRANI KN, Abou-Hamad J, Pascoal J, Labreche C, et al
    Correction to: AKT-mediated phosphorylation of Sox9 induces Sox10 transcription in a murine model of HER2-positive breast cancer.
    Breast Cancer Res. 2021;23:60.
    PubMed        
    
    

    
    Breast Cancer Res Treat

23. JOOSEN MEM, Schop SJ, Reinhoudt LL, van Kuijk SMJ, et al
    The difference in local, regional and distant breast cancer recurrence between the immediate and delayed DIEP flap procedure; a retrospective cohort study.
    Breast Cancer Res Treat. 2021 May 24. pii: 10.1007/s10549-021-06199.
    PubMed         Abstract available
    
    
24. HARATI R, Mabondzo A, Tlili A, Khoder G, et al
    Combinatorial targeting of microRNA-26b and microRNA-101 exerts a synergistic inhibition on cyclooxygenase-2 in brain metastatic triple-negative breast cancer cells.
    Breast Cancer Res Treat. 2021 May 26. pii: 10.1007/s10549-021-06255.
    PubMed         Abstract available
    
    
25. MILLER MM, Meneveau MO, Rochman CM, Schroen AT, et al
    Impact of the COVID-19 pandemic on breast cancer screening volumes and patient screening behaviors.
    Breast Cancer Res Treat. 2021 May 25. pii: 10.1007/s10549-021-06252.
    PubMed         Abstract available
    
    
26. TRAPANI D, Giugliano F, Uliano J, Zia VAA, et al
    Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review.
    Breast Cancer Res Treat. 2021 May 27. pii: 10.1007/s10549-021-06259.
    PubMed         Abstract available
    
    

    
    Cancer

27. DHAKAL A, Falkson C, O'Regan RM
    Adjuvant cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive breast cancer: One Monarch to rule them all?
    Cancer. 2021 May 28. doi: 10.1002/cncr.33650.
    PubMed         Abstract available
    
    
28. PRINTZ C
    Female breast cancer most commonly diagnosed cancer globally.
    Cancer. 2021;127:1952-1953.
    PubMed        
    
    
29. PRINTZ C
    Some patients with postmenopausal breast cancer can avoid adjuvant chemotherapy: Data indicate that some postmenopausal women with breast cancer can safely skip adjuvant chemotherapy.
    Cancer. 2021;127:1951-1952.
    PubMed        
    
    

    
    Cancer Chemother Pharmacol

30. PATTARAWAT P, Hunt JT, Poloway J, Archibald CJ, et al
    A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis.
    Cancer Chemother Pharmacol. 2021 May 27. pii: 10.1007/s00280-021-04298.
    PubMed         Abstract available
    
    

    
    Cancer Lett

31. PROVANCE OK, Geanes ES, Lui AJ, Roy A, et al
    Disrupting interferon-alpha and NF-kappaB crosstalk suppresses IFITM1 expression attenuating triple-negative breast cancer progression.
    Cancer Lett. 2021;514:12-29.
    PubMed         Abstract available
    
    
32. LI X, Wang H, Yang X, Wang X, et al
    GABRP sustains the stemness of triple-negative breast cancer cells through EGFR signaling.
    Cancer Lett. 2021 May 20. pii: S0304-3835(21)00194.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

33. SILVA FR, Grande AJ, Lacerda Macedo AC, Colonetti T, et al
    Meta-Analysis of Breast Cancer Risk in Levonorgestrel-Releasing Intrauterine System Users.
    Clin Breast Cancer. 2021 Apr 3. pii: S1526-8209(21)00068.
    PubMed         Abstract available
    
    
34. CASEY DL, Gupta GP, Ollila DW
    The Role of Intraoperative Radiation in Early-stage Breast Cancer.
    Clin Breast Cancer. 2021;21:103-111.
    PubMed         Abstract available
    
    
35. LEE Y, Kang E, Shin HC, Lee H, et al
    The Effect of Body Mass Index on Initial Breast Cancer Stage Among Korean Women.
    Clin Breast Cancer. 2021 Apr 22. pii: S1526-8209(21)00085.
    PubMed         Abstract available
    
    
36. VILLARREAL-GARZA C, Ferrigno AS, Mesa-Chavez F, Platas A, et al
    Improving Collection of Real-World Data: The Experience of the Joven & Fuerte Prospective Cohort for Mexican Young Women With Breast Cancer.
    Clin Breast Cancer. 2021 Apr 20. pii: S1526-8209(21)00083.
    PubMed         Abstract available
    
    
37. SHAPIRO CL
    Bone-modifying Agents (BMAs) in Breast Cancer.
    Clin Breast Cancer. 2021 Apr 26. pii: S1526-8209(21)00087.
    PubMed         Abstract available
    
    
38. WITT JS, Wisinski KB, Anderson BM
    Concurrent Radiation and Modern Systemic Therapies for Breast Cancer: An Ever-Expanding Frontier.
    Clin Breast Cancer. 2021;21:120-127.
    PubMed         Abstract available
    
    

    
    CMAJ

39. MCCUTCHEON S
    The butterfly.
    CMAJ. 2021;193:E27-E28.
    PubMed        
    
    

    
    Eur J Surg Oncol

40. SCHIPPER RJ, de Bruijn A, Voogd AC, Bloemen JG, et al
    Rate and predictors of nodal pathological complete response following neoadjuvant endocrine treatment in clinically biopsy-proven node-positive breast cancer patients.
    Eur J Surg Oncol. 2021 May 18. pii: S0748-7983(21)00474.
    PubMed         Abstract available
    
    

    
    Gene

41. ROYCHOWDHURY A, Jondhale M, Saldanha E, Ghosh D, et al
    Landscape of Toll-like receptors expression in tumor microenvironment of Triple Negative Breast Cancer (TNBC): distinct roles of TLR4 and TLR8.
    Gene. 2021 May 19:145728. doi: 10.1016/j.gene.2021.145728.
    PubMed         Abstract available
    
    
42. FENG Y, Cai H, Huang X, Li Z, et al
    Active MT1-MMP is tethered to collagen fibers in DDR2-containing remnants.
    Gene. 2021;788:145673.
    PubMed         Abstract available
    
    

    
    Int J Cancer

43. HAGENAARS SC, de Groot S, Cohen D, Dekker TJA, et al
    Tumor-stroma ratio is associated with Miller-Payne score and pathological response to neoadjuvant chemotherapy in HER2-negative early breast cancer.
    Int J Cancer. 2021 May 27. doi: 10.1002/ijc.33700.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

44. MUTTER RW, Choi JI, Jimenez RB, Kirova YM, et al
    Proton Therapy for Breast Cancer: A Consensus Statement from the Particle Therapy Cooperative Group (PTCOG) Breast Cancer Subcommittee.
    Int J Radiat Oncol Biol Phys. 2021 May 25. pii: S0360-3016(21)00652.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

45. MOSKOWITZ CS, Ronckers CM, Chou JF, Smith SA, et al
    Development and Validation of a Breast Cancer Risk Prediction Model for Childhood Cancer Survivors Treated With Chest Radiation: A Report From the Childhood Cancer Survivor Study and the Dutch Hodgkin Late Effects and LATER Cohorts.
    J Clin Oncol. 2021 May 28:JCO2002244. doi: 10.1200/JCO.20.02244.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

46. CUI W, Francis PA, Loi S, Hickey M, et al
    Assessment of Ovarian Function in Phase 3 (Neo)adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation.
    J Natl Cancer Inst. 2021 May 28. pii: 6287661. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

47. REITSAMER R, Peintinger F, Klaassen-Federspiel F, Sir A, et al
    The iBAG study-a milestone?
    J Surg Oncol. 2021;123:1845.
    PubMed        
    
    
48. GONZALEZ-WOGE MA, Martin-Tellez KS, Gonzalez-Woge R, Teran-De-la-Sancha K, et al
    Inadequate prediction of postoperative complications in breast cancer surgery: An evaluation of the ACS Surgical Risk Calculator.
    J Surg Oncol. 2021 May 24. doi: 10.1002/jso.26529.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

49. WILLIAMS MM, Christenson JL, O'Neill KI, Hafeez SA, et al
    MicroRNA-200c restoration reveals a cytokine profile to enhance M1 macrophage polarization in breast cancer.
    NPJ Breast Cancer. 2021;7:64.
    PubMed         Abstract available
    
    
50. WANG X, Wang L, Bu H, Zhang N, et al
    How can artificial intelligence models assist PD-L1 expression scoring in breast cancer: results of multi-institutional ring studies.
    NPJ Breast Cancer. 2021;7:61.
    PubMed         Abstract available
    
    
51. VEERARAGHAVAN J, Gutierrez C, Sethunath V, Mehravaran S, et al
    Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models.
    NPJ Breast Cancer. 2021;7:63.
    PubMed         Abstract available
    
    

    
    Oncol Rep

52. ZONG B, Sun L, Peng Y, Wang Y, et al
    HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance.
    Oncol Rep. 2021;46.
    PubMed         Abstract available
    
    

    
    PLoS One

53. VELAZQUEZ FN, Zhang L, Viscardi V, Trocchia C, et al
    Loss of sphingosine kinase 1 increases lung metastases in the MMTV-PyMT mouse model of breast cancer.
    PLoS One. 2021;16:e0252311.
    PubMed         Abstract available
    
    
54. KIM HS, Kim MG, Min KW, Jung US, et al
    High MMP-11 expression associated with low CD8+ T cells decreases the survival rate in patients with breast cancer.
    PLoS One. 2021;16:e0252052.
    PubMed         Abstract available
    
    
55. NG DY, Tudor Car L, Ng MJM, Lu J, et al
    Identifying barriers to early presentation in patients with locally advanced breast cancer (LABC) in Northern Singapore: Qualitative study.
    PLoS One. 2021;16:e0252008.
    PubMed         Abstract available
    
    

    
    Radiology

56. CHANG JM
    MRI Screening Interval in Women with a History of Breast Cancer.
    Radiology. 2021 May 25:210836. doi: 10.1148/radiol.2021210836.
    PubMed        
    
    
57. PARK VY, Kim MJ, Kim GR, Yoon JH, et al
    Outcomes Following Negative Screening MRI Results in Korean Women with a Personal History of Breast Cancer: Implications for the Next MRI Interval.
    Radiology. 2021 May 25:204217. doi: 10.1148/radiol.2021204217.
    PubMed         Abstract available
    
    

    
    Science

58. FISH L, Khoroshkin M, Navickas A, Garcia K, et al
    A prometastatic splicing program regulated by SNRPA1 interactions with structured RNA elements.
    Science. 2021;372.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: